Perfusion Assessment in Laparoscopic Left Anterior Resection (PILLAR II)
Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures
Sponsor: Novadaq Technologies ULC, now a part of Stryker
Listed as NCT01560377, this PHASE1 trial focuses on Colon Cancer and Crohn's Disease and remains completed. Sponsored by Novadaq Technologies ULC, now a part of Stryker, it has been updated 11 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1
▶ Show 6 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2019 — Mar 2019 [monthly]
Completed PHASE1
-
Nov 2018 — Jan 2019 [monthly]
Completed PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novadaq Technologies ULC, now a part of Stryker
For direct contact, visit the study record on ClinicalTrials.gov .